Incretin agonists show potential in obesity treatment amid safety concerns

New developments in obesity pharmacology are highlighting the potential of incretin mimetics, specifically triple agonists like retatrutide. This experimental injectable drug targets three hormone receptors—GLP-1, GIP, and glucagon—to coordinate insulin secretion, reduce hunger, and modulate energy metabolism. Clinical studies have indicated weight reductions of approximately 30 percent, though these results stem from controlled phase 3 trials rather than routine clinical practice.

Existing therapies, such as semaglutide and tirzepatide (used under brands like Ozempic, Wegovy, Mounjaro, and Zepbound), have already transformed the treatment of type 2 diabetes and clinical obesity by mimicking intestinal hormones to slow gastric emptying and suppress appetite.

However, medical experts warn of risks associated with the uncontrolled use of these medications. When used off-label for purely aesthetic purposes by individuals who are not clinically obese, the risk-benefit ratio shifts. Potential complications from improper use or lack of clinical supervision include severe gastroparesis and paralytic ileus.